A Phase I Study of LFA102 in Japanese Patients

• Status: Completed
• Trial end date: 2014-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate safety and tolerability to determine the MTD/RD.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals

Criteria

Inclusion Criteria:

• Histologically confirmed diagnosis of prostate cancer

• Histologically or cytologically confirmed locally advanced or metastatic breast cancer

Exclusion Criteria:

• Patients with untreated and/or symptomatic metastatic CNS disease

• Prior anaphylactic or other severe infusion reaction

• Treatment with agent which affect prolactin levels

• Active autoimmune disease

Other protcol-defined Inclusion/Exclusion criteria may apply.